Bloomberg News, November 1, 2023: Sarepta’s gene therapy Elevidys failed to confirm efficacy for Duchenne Muscular Dystrophy. Will FDA convert accelerated approval to full approval anyway? We explain why that would be ridiculous, but not impossible. But who will pay for an unproven treatment that costs $3.2 million per patient?
Read More »Author: Caroline Bradford
Letter to NJ officials in Montclair and Essex County Regarding Harms from Artificial Turf
October 30, 2023: NCHR president Dr. Diana Zuckerman wrote a letter to NJ officials in Montclair and Essex County explaining why lead, PFAS, and other chemicals in artificial turf and rubber playground surfaces harm children’s health and safety.
Read More »NCHR’s Comments on Proposed Supplemental Guidance for CPSC Chronic Hazard Guidelines
NCHR criticizes CPSC’s revised proposal for chronic hazard guidelines for focusing on linear modeling that is not appropriate for endocrine disrupting chemical and for including a loophole that enables companies to do whatever they think is scientifically appropriate. We urge the CPSC to produce more explicit, rigorous guidelines based on sound science, since that is essential for the safety of consumers.
Read More »Are PIP rubber playgrounds safe for Kingston?
Kingston Wire, October 23, 2023: NCHR president Diana Zuckerman’s oped in the Kingston (NY) Wire explains the risks to children of lead and other toxic chemicals in PIP rubber playground surfaces and artificial turf in Kingston and other communities.
Read More »Experts fear FDA push to get neurological drugs to market faster shortchanges patients
Politico Pro, October 20, 2023: Politico news story explains that FDA’s accelerated approval of neurological drugs shortchanges patients who have lobbied for it because these very expensive drugs aren’t proven to work
Read More »